{"filing":{"accession_number":"0001193125-26-314167","cik":"0001835579","ticker":"IMA","company_name":"ImageneBio, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"d143178d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526314167/d143178d8k.htm"},"events":[{"id":20108,"run_id":18101,"accession_number":"0001193125-26-314167","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer effective July 20, 2026, with a base salary of $450,000, 40% bonus eligibility, RSU and option grants, and severance benefits.","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19383,"accession_number":"0001193125-26-314167","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer effective July 20, 2026. While the disclosure also includes compensatory arrangements (base salary of $450,000, 40% bonus eligibility, RSU and option grants, and severance benefits), the principal disclosed action is the appointment of a named executive to a C-suite officer role. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:26:42.059144+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":20109,"run_id":18101,"accession_number":"0001193125-26-314167","anchor_item_number":"8.01","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Benjamin Porter-Brown, Chief Medical Officer, transitioned from his full-time executive position to a consulting role effective July 24, 2026.","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19384,"accession_number":"0001193125-26-314167","item_number":"8.01","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Benjamin Porter-Brown, the Chief Medical Officer, is transitioning from his full-time executive position to a consulting role effective July 24, 2026. While he remains involved in a consulting capacity, the principal disclosed action is the departure from his full-time officer role, which is material to investors assessing the company's clinical leadership and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:26:42.059144+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19383,"accession_number":"0001193125-26-314167","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer effective July 20, 2026. While the disclosure also includes compensatory arrangements (base salary of $450,000, 40% bonus eligibility, RSU and option grants, and severance benefits), the principal disclosed action is the appointment of a named executive to a C-suite officer role. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:26:42.059144+00:00","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-07-23"},{"id":19384,"accession_number":"0001193125-26-314167","item_number":"8.01","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Benjamin Porter-Brown, the Chief Medical Officer, is transitioning from his full-time executive position to a consulting role effective July 24, 2026. While he remains involved in a consulting capacity, the principal disclosed action is the departure from his full-time officer role, which is material to investors assessing the company's clinical leadership and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:26:42.059144+00:00","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-07-23"}]}